• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

EE568 Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis
Alteplase is widely used as intravenous thrombolytic medication in acute ischemic stroke (AIS). However, tenecteplase, a genetically modified form of alteplase, has recently been shown to result in higher recanalization rates, improved functional outcome and a similar safety profile in AIS patients with large vessel occlusion (LVO) compared to alteplase. Accordingly, this study aims to evaluate the cost-effectiveness of 0.25mg/kg tenecteplase versus 0.9mg/kg alteplase for thrombolysis in AIS patients due to LVO from the Dutch healthcare payer perspective.
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: C Nguyen, MMH Lahr, DJ Van der Zee, H Van Voorst, YBWEM Roos, M Uyttenboogaart, E Buskens Source Type: research

EE477 Budgetary Impact Analysis of Alteplase - Recombinant Tissue Plasminogen Activator (RTPA) - As a Thrombolytic Treatment for Acute Ischemic Stroke in Colombia
to evaluate the potential impact on costs and health outcomes of increasing the proportion of patients with acute ischemic stroke (AIS) who are thrombolyzed with alteplase in Colombia and of reducing the time to initiate treatment.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: P Lasalvia Source Type: research

Cost-Effectiveness of Edoxaban In Patients With Non-Valvular Atrial Fibrillation In Hong Kong
Atrial fibrillation (AF) is a common arrhythmia associated with debilitating consequences such as stroke, heart failure and venous thromboembolism. In HK, 20-25% of stroke cases are related to AF leading to a significant burden. Warfarin has been the frontline oral anticoagulant for AF but with high bleeding risk and hence monitoring and dose adjustment are required. The non-vitamin-K antagonist oral anticoagulants (NOACs) are alternatives to warfarin for preventing stroke and systemic embolism in non-valvular AF (NVAF) patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: DB Wu, WY Choon, KK Lee Source Type: research

Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?
To quantify the potential value of new research in patients treated with thrombolytic treatment (tissue-type plasminogen activator [tPA]) in the 4.5- to 6.0-hour time window after stroke onset and to determine the optimal size of a future trial using value of information analysis.
Source: Value in Health - April 29, 2017 Category: Global & Universal Authors: Dj øra I. Soeteman, Nicolas A. Menzies, Ankur Pandya Source Type: research

Relationship of Time in Therapeutic Range (Ttr) with Bleeding and Stroke Incidences of Warfarinised Patients with Pulmonary Embolism in a Tertiary Hospital in Malaysia
This study aims to compare time in therapeutic range (TTR) of warfarin in patients with pulmonary embolism with bleeding and stroke and determine reasons of INR falling out of range.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: N Sudirman, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research

Impact On Italian National Health Service Expenditure For The Treatment Of Venous Thromboembolism With Rivaroxaban
This study aims to evaluate the economic impact of the use of rivaroxaban for preventing DVT and PE in Italy.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Roggeri, DP Roggeri, V Pengo Source Type: research

Cost Savings By The Use Of Bemiparin In The Treatment Of Patients With Venous Thromboembolism In Spain
Venous thromboembolism (VTE) is the third most common cause of death from cardiovascular disease after acute MI and stroke. Initial treatment of VTE using heparin or LMWH has been recommended by different international guidelines. The aim of this study was to analyze the economic impact that could represent the use of bemiparin compared with the conventional treatment in Spain.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: C Pinyol, B Navarro, JM Fernández-Lomana, C Gutiérrez Source Type: research

Cost-Effectiveness Analysis Of Bemiparin Used As Acute Treatment For Deep Venous Thrombosis Without Pulmonary Embolism
Deep venous thrombosis (DVT) and pulmonary embolism (PE) comprise venous thromboembolism (VTE), the third most common cardiovascular illness after acute coronary syndrome and stroke and a raising public health concern due to its morbity and mortality and higher costs. Acute and long term treatments help to avoid complications. We assessed the costs and effectiveness of different regimens for treatment of DVT without PE under the perspective of the Mexican public health system.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Aguirre, F Carlos, M Naranjo, C Fernandez Source Type: research

Study On Drug Utilization And Assessment Of Stroke Risk Using Chads2 And Cha2ds2-Vasc Scoring In Elderly Patients With Non-Valvular Atrial Fibrillation
Stroke Risk Stratification in AF patients of can be done using CHADS2 (Congestive heart failure, Hypertension, Age ≥75, DM, prior Stroke/TIA [2 points] ); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection fraction ≤35%, Hypertension, Age ≥75 [2 points], DM, prior Stroke/TIA/thromboembolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets (Aspirin and Clopidogrel).
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: T. Raj, S. Bonthu, S.R. Mallayasamy Source Type: research

Development Of A Collaborative European Pharmacoepidemiologic Post-Authorization Safety Study (Pass) Programme Examining Rivaroxaban Use In Routine Clinical Practice
Proactive, post-authorization monitoring of drug safety and effectiveness is of increasing importance. Rivaroxaban is a Factor Xa inhibitor with multiple indications, including: treatment of venous thromboembolism (VTE) and prevention of recurrent VTE; stroke prevention in atrial fibrillation; and prevention of atherothrombotic events (when combined with antiplatelet therapy) following an acute coronary syndrome. Use, safety and effectiveness of rivaroxaban in real-life settings need to be monitored to understand its value and comply with regulatory requirements.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: G. Brobert, Rodríguez L.A. García, E. Garbe, I.D. Bezemer, D. Layton, L. Friberg, K. Suzart-Woischnik, J. Alderson, C. Winchester, R.M.C. Herings, K. Jobski, T. Schink, S. Shakir, M. Soriano-Gabarró, M.A. Wallander Source Type: research

Budget Impact of Left Atrial Appendage Occulusion in Patients with Atrial Fibrillation Contraindicated to Anticoagulation
Stroke is a leading public health problem in terms of mortality and economic burden in Korea. Anticoagulants are the mainstay for ischemic stroke prevention in atrial fibrillation (AF), but many patients have contraindications to these drugs. A number of catheter-based left atrial appendage occlusion (LAAO) devices devised to eliminate the major cause of thromboembolism in AF patients have been commercialized in Europe but are not yet available in Korea. The purpose of this study is to perform a budget impact analysis of LAAO in patients with AF contraindicated to anticoagulation.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: J.W. Park, M. Koullick, E. Han Tags: CARDIOVASCULAR DISORDERS - Cost Studies Source Type: research

Acute Ischemic Stroke (Ais) Patient Management in French Stroke Units and Impact Estimation of Thrombolysis On Care Pathways and Associated Costs
This study aims to evaluate the current management and associated costs of acute ischemic stroke (AIS) for patients admitted in stroke units in France and over a 1 year follow-up period as well as to assess the impact of improved thrombolytic management in terms of increasing the proportion of patients receiving thrombolysis and/or treated within 3hrs from symptom onset on functional recovery and care pathways.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: A. Schmidt, S. Bénard, C. Heroum, D. Caumette, O. Delaitre, Lay K. Le Source Type: research